Rapid growth for Pacira Pharmaceuticals' time-release surgical painkiller Exparel is lifting profit as sales are leveraged against fixed costs, but a bigger opportunity may be ahead if the company can execute on plans to boost Exparel's addressable market.If so, the rapid run-up in Pacira Pharmaceuticals shares in October may be the start, rather than the end, for this company.
Continue Reading Below
The article Why Pacira Pharmaceuticals Shot Higher Last Month originally appeared on Fool.com.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.